The 17 gene assay (Oncotype Dx Genomic Prostate Score, GPS) is a validated, biopsybased commercial gene expression assay that, combined with clinical features, provides an individual estimate of disease aggressiveness at the time of PCa diagnosis. We report interim study results on the impact of GPS on the management of clinically low risk PCa patients in community-based urology practices.
INTRODUCTION AND OBJECTIVES:
The 17 gene assay (Oncotype Dx Genomic Prostate Score, GPS) is a validated, biopsybased commercial gene expression assay that, combined with clinical features, provides an individual estimate of disease aggressiveness at the time of PCa diagnosis. We report interim study results on the impact of GPS on the management of clinically low risk PCa patients in community-based urology practices.
METHODS: 1,200 patients were prospectively enrolled from 26 sites. For this interim analysis, we report 1 year outcomes in the first 297 patients with valid GPS results. The primary endpoints were GPS' impact on initial management and persistence on active surveillance (AS) at 1 year post-diagnosis in patients who chose to pursue AS. Rates of AS utilization and persistence in GPS tested patients were compared with a group of 247 patients who did not have genomic testing managed in the same practices (baseline cohort). Descriptive statistics were reported. Analyses were conducted using SAS 9.4. RESULTS: One-year results were available in 258/297 tested patients (26% NCCN VL, 43% Low and 31% Intermediate). Both utilization and persistence on AS were higher in the GPS-tested cohort (62% vs 40% AS adoption and 89% vs 86% AS persistence) at 1 year. Higher utilization and persistence on AS resulted in a 21% absolute increase in the proportion of men on AS at 1 year postdiagnosis in the GPS tested cohort compared to and baseline ( Figure  1 ). Net increases of patients on AS at 1 year were seen across age groups (59% vs. 41% in >¼65yrs, and 51% vs. 29% in <65 yrs), and racial groups (51% vs. 39% in African American, and 55% vs. 33% in all other racial groups).
CONCLUSIONS: Patients, especially younger men, and physicians who received GPS were more likely to pursue AS for initial management than untested patients. Overall utilization of AS was 62% higher in GPS tested vs. untested patients at 1 year post-diagnosis. The individual risk refinement provided by genomic testing demonstrates the impact of the GPS in identifying appropriate patients and supporting more AS decisions in clinically low risk PCa.
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MP28-12 IMPACT OF LYMPHOVASCULAR INVASION ON LYMPH NODE METASTASIS FOR T3 PATIENTS UNDERGOING RADICAL PROSTATECTOMY IN CONSIDERATION OF RESECTION MARGIN STATUS
Yong Jin Kang*, Won Sik Jang, Myung Soo Kim, Won Sik Jung, Cheol Yong Yoon, Seoul, Korea, Republic of; In Rae Cho, Gimhae, Korea, Republic of; Young Deuk Choi, Seoul, Korea, Republic of INTRODUCTION AND OBJECTIVES: To assess an association between the increased risk of biochemical recurrence and lymphovascular invasion in T3 margin positive or negative patients and its association with lymph node metastasis.
METHODS: 1634 patients who underwent radical prostatectomy from 2005 to 2014 were selected. Patients with bone or distant organ metastasis at the time of operation were excluded. Survival analysis was performed to assess biochemical recurrence, bone metastasis and mortality risks by Kaplan-Meier analysis and multivariate Cox proportional hazard regression. Odds of lymph node metastasis were evaluated by Logistic regression.
RESULTS: LVI was detected in 118 (7.4%) patients. The median follow-up duration was 33.1 months. In the Kaplan-Meier analysis, lymphovascular invasion was associated with significantly shorter biochemical recurrence free survival (39.3 vs. 82.5 months, p<0.001), bone metastasis-free survival (134.4 vs. 156.7 months, p¼0.001) and cancer specific survival (122.7 vs. 152.6 months, p¼0.034). When stratified by T stage and resection margin status, lymphovascular invasion resulted in significantly shorter biochemical recurrence-free duration in T3 patients with and without positive surgical margin (p¼0.008, 0.005, respectively). In the multivariate Cox regression model lymphovascular invasion resulted in 1.4-fold risk increase (95% CI 1.05-1.75, p¼0.031).Lymphovascular invasion was revealed to be strongly associated with lymph node metastasis in the multivariate Logistic regression (OR 4.26, 95% CI 2.07-8.79, p<0.001).
CONCLUSIONS: Lymphovascular invasion increased the risk of early recurrence in T3 patients regardless of margin status, by accelerating the metastasis.
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